Can-Fite Biopharma Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 11, 2027The maintenance fee for Process for the synthesis of IB-MECA (US 9,102,698) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,265,337 | Use of A3 Adenosine Receptor Agonist in Osteoarthritis Treatment In force · Medium confidence | In force | Medium confidence | |
| US 8,846,635 | Method for inducing hepatocyte proliferation and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,387,220 | Method for inducing hepatocyte proliferation and uses thereof In force · USPTO record | In force | USPTO record | |
| US 9,102,698 | Process for the synthesis of IB-MECA In force · USPTO record | In force | USPTO record | |
| US 8,987,228 | Pharmaceutical Composition Comprising A3 Adenosine Receptor Agonist (IB-MECA/CF-101) for Treatment of Psoriasis In force · High confidence | In force | High confidence | |
| US 9,549,943 | A3 Adenosine Receptor Ligands for Use in Treatment of a Sexual Dysfunction In force · High confidence | In force | High confidence | |
| US 10,780,106 | Method for Treating Nash Accompanied by Fibrosis Using Ci-Ib-Meca In force · High confidence | In force | High confidence | |
| US 11,291,681 | Method for Treating Fibrotic Liver Tissue Using Cl-Ib-Meca In force · High confidence | In force | High confidence | |
| US 12,213,990 | An A3 Adenosine Receptor Ligand for Use for Achieving a Fat Loss Effect In force · High confidence | In force | High confidence |
Also on record, not counted in the 9: 11 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 3 abandoned · 12 no status recorded